查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2029993

間質幹細胞市場－全球產業規模、佔有率、趨勢、機會和預測：按產品/服務、工作流程、類型、來源、適應症、應用、地區和競爭格局分類，2021-2031年

Mesenchymal Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Services, By Workflow, By Type, By Source of Isolation, By Indication, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球間質幹細胞市場預計將從 2025 年的 29.8 億美元成長到 2031 年的 49.5 億美元，複合年成長率為 8.83%。

間質幹細胞（MSCs）是多功能基質細胞，其特徵在於能夠黏附於塑膠表面、表達獨特的表面標誌物，並能分化為脂肪細胞、軟骨細胞和成骨細胞。這項市場擴張主要得益於再生醫學的持續進步、研發投入的增加，以及這些治療方法在心血管疾病和骨關節炎等退化性疾病的應用日益廣泛。臨床試驗的積極結果進一步加速了這一進程。為了支持這項強勁的臨床應用，臍帶血家長指南基金會報告稱，2025年上半年，全球註冊機構共記錄了89項MSC臨床試驗。

市場概覽
預測期 2027-2031
市場規模：2025年 29.8億美元
市場規模：2031年 49.5億美元
複合年成長率：2026-2031年 8.83%
成長最快的細分市場 現成型
最大的市場 北美洲

儘管前景樂觀，但該行業仍面臨許多挑戰。首要因素是間質幹細胞（MSC）研究、生產和臨床應用的高成本。此外，各地區法律規範的複雜性和多樣性，以及細胞分離和增殖方面對統一方案的持續需求，都對市場的廣泛滲透構成了重大障礙。倫理問題和高效規模化生產能力的問題仍然是必須解決的關鍵挑戰，以確保市場的長期成長。

市場促進因素

退化性疾病疾病和慢性疾病的日益普遍是全球間間質幹細胞市場的主要驅動力，也使得亟需尖端治療性介入的患者群體不斷擴大。心血管疾病、骨關節炎和神經系統疾病在全球呈上升趨勢，對突破性治療方法的需求日益強勁。間質幹細胞已展現出治療這些嚴重的巨大再生潛力，使其成為治療研究的重點。再生醫學聯盟發布的《2025年第三季產業概況》也印證了這一點，該報告指出，帕金森氏症將影響全球超過1,000萬人，凸顯了間質幹細胞療法旨在解決的巨大未滿足需求。日益加重的疾病負擔要求我們持續投入資金，並進一步改善間質幹細胞技術。

另一個關鍵的成長要素是幹細胞研究領域私人和公共資金的激增。這確保了必要的資金支持，使治療方法能夠從早期發現階段推進到臨床試驗，最終推向市場。充足的資金支持著全面的研發活動，包括關鍵的臨床試驗和可擴展生產方法的建立。正如再生醫學聯盟在2026年1月發布的《相信的理由》報告中所述，2025年細胞和基因治療產業透過216輪資金籌措共籌集了111億美元，反映出強勁的投資環境。這些資金支持加速了科學發現，並簡化了從治療方法到患者的昂貴流程。此外，《間質幹細胞新聞》在2025年8月報道稱，ClinicalTrials.gov網站上有超過1100項正在進行的間質幹細胞臨床試驗，凸顯了這項全球投資所帶來的蓬勃發展的臨床活動。

市場挑戰

阻礙全球間間質幹細胞市場成長的一大障礙是研發、生產和臨床應用所需的巨額資金投入。這些高昂的成本直接導致基於間質幹細胞療法的治療費用居高不下，從而限制了患者獲得治療的機會，也限制了其在全球醫療體系中的廣泛應用。在長期臨床開發階段，此經濟負擔尤其突出，因為該階段需要大量資金來驗證其安全性和有效性。為了凸顯這一前沿醫學領域持續發展所需的巨額資金，再生醫學聯盟報告稱，到2025年，包括間質幹細胞在內的細胞和基因治療領域將透過216資金籌措獲得111億美元的資金。

這些資金限制也阻礙了中小型生物技術公司進入市場開發新產品，導致創新集中在大公司手中，並有可能減緩市場擴張和治療方法多樣化。建造合規生產設施和應對複雜的監管流程所需的大量資金進一步加劇了這一問題，構成了市場廣泛滲透的重大障礙。

市場趨勢

向現成間間質幹細胞療法的轉變是重要的行業趨勢，它解決了自體療法的一些關鍵缺陷，例如高成本、生產過程複雜以及規模化應用受限。透過利用易於獲取的供體來源，例如誘導多功能能幹細胞（iPS細胞），這些現成療法為統一、便捷的治療方法鋪平了道路，簡化了供應鏈並擴大了患者的治療範圍。這種方法最大限度地減少了供體差異，提高了最終產品的可靠性和療效。例如，Cynata Therapeutics在其2025年3月的季度活動中報告稱，其用於治療骨關節炎的iPS細胞衍生間質幹細胞療法「CYP-004」的III期臨床試驗已成功招募了321名受試者，這體現了這些現成解決方案的應用範圍不斷擴大和臨床進展日趨成熟。

同時，無細胞療法和間質幹細胞（MSC）來源的外泌體的出現是一項重大突破，它將研究重點從活細胞移植轉向間接利用MSC的修復特性。外泌體作為奈米級載體，能夠運輸細胞間通訊所必需的生物分子，與活細胞相比具有顯著優勢，包括更高的安全性、更低的免疫反應以及更簡單的儲存和給藥方式。這項發展使得利用MSC的旁分泌功能，避免活細胞給藥固有的併發症，從而為多種疾病開發新的治療策略。 Medical Buyer報告稱，美國公司Mdxhealth於2025年9月以1500萬美元的價格從Bio-Techne手中收購了Exosome Diagnostics，這反映了該領域日益成長的商業性吸引力，也凸顯了外泌體技術創新所獲得的強勁資金支持和市場價值。

目錄

第1章 產品概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球間質幹細胞市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品/服務分類（產品（細胞/細胞株、試劑盒、培養基/試劑、其他）、服務）
    • 工作流程分解（細胞製備/分離、培養/冷凍保存、分化、特性化）
    • 按類型（自家繁殖、同種異體）
    • 分離來源（骨髓、臍帶血、周邊血、輸卵管、胎兒肝臟、肺臟、脂肪組織）
    • 適應症（骨骼和軟骨修復、心血管疾病、發炎和免疫性疾病、肝病、癌症、移植物抗宿主疾病等）
    • 按應用領域（疾病建模、藥物發現/新藥開發、幹細胞庫、組織工程、毒性測試等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美間間質幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲間間質幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區間間質幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲間間質幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲間間質幹細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球間質幹細胞市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc
  • Cell Applications, Inc
  • Axol Biosciences Ltd
  • Cytori Therapeutics Inc
  • StemCell Technologies Canada Inc.
  • Cyagen Biomodels LLC
  • Celprogen Inc
  • BrainStorm Cell Limited
  • Stemedica Cell Technologies Inc
  • Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16246

The Global market for mesenchymal stem cells is expected to expand from USD 2.98 billion in 2025 to USD 4.95 billion by 2031, reflecting a compound annual growth rate of 8.83%. Mesenchymal stem cells (MSCs) are multipotent stromal cells characterized by their ability to stick to plastic, display distinct surface markers, and transform into adipocytes, chondroblasts, and osteoblasts. This market's expansion is largely fueled by continuous progress in regenerative medicine, heightened investments in research and development, and the widening use of these therapies for degenerative and chronic illnesses like cardiovascular disorders and osteoarthritis. Positive outcomes from clinical trials add further momentum to this progress. Highlighting this strong clinical involvement, the Parent's Guide to Cord Blood Foundation reported that 89 MSC trials were logged in global registries during the first six months of 2025.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.98 Billion
Market Size 2031USD 4.95 Billion
CAGR 2026-20318.83%
Fastest Growing SegmentAllogenic
Largest MarketNorth America

Even with this optimistic trajectory, the industry faces substantial hurdles, primarily due to the steep expenses tied to the research, production, and clinical application of MSCs. Furthermore, the complex and diverse regulatory frameworks across various regions, along with the ongoing necessity for uniform protocols in cell isolation and expansion, create significant barriers to broad market adoption. Matters related to ethical concerns and the ability to scale up manufacturing efficiently remain crucial obstacles that must be addressed to ensure long-term market growth.

Market Driver

The increasing incidence of degenerative and chronic illnesses acts as a major catalyst for the global mesenchymal stem cells market, broadening the base of patients who desperately require cutting-edge therapeutic interventions. Ailments like cardiovascular diseases, osteoarthritis, and neurological conditions are becoming more common globally, generating a strong demand for breakthrough treatments. Because MSCs present encouraging regenerative potential for these severe disorders, they have become a primary focus in therapeutic research. Illustrating this point, the Alliance for Regenerative Medicine's Q3 2025 Sector Snapshot noted that Parkinson's disease affects more than 10 million people globally, emphasizing the massive unmet clinical needs that MSC treatments strive to fulfill. This mounting burden of disease demands ongoing funding and the further refinement of MSC technologies.

Another essential growth driver is the surge in both private and public financial support for stem cell studies, which delivers the necessary capital to move therapies from early-stage discovery to clinical testing and market launch. This wealth of funding sustains comprehensive research and development efforts, encompassing vital clinical trials and the creation of scalable production methods. As noted in the Alliance for Regenerative Medicine's January 2026 'Reasons to Believe' report, the broader cell and gene therapy industry secured $11.1 billion across 216 financing rounds in 2025, reflecting a powerful investment climate. This financial backing speeds up scientific discoveries and facilitates the expensive journey of bringing treatments from the lab to patients. Moreover, Mesenchymal Stem Cell News reported in August 2025 that ClinicalTrials.gov featured more than 1,100 active MSC trials, highlighting the intense clinical activity made possible by these global investments.

Market Challenge

A major obstacle hindering the growth of the global mesenchymal stem cells market is the massive financial investment necessary for research, production, and clinical execution. Such exorbitant expenses directly lead to the steep costs of MSC-based treatments, thereby limiting patient access and broader integration into healthcare systems worldwide. This economic strain is especially evident during the lengthy stages of clinical development, which demand heavy funding to establish both safety and effectiveness. Highlighting the immense capital needed to maintain progress in this cutting-edge medical arena, the Alliance for Regenerative Medicine reported that the cell and gene therapy sector, encompassing MSCs, secured $11.1 billion through 216 funding events in 2025.

These financial constraints also restrict the involvement of smaller biotech companies in the development of new products, consequently centralizing innovation within larger corporations and risking a slowdown in market expansion and therapeutic variety. The steep capital requirements needed to build compliant production facilities and successfully maneuver through complex regulatory channels worsen this problem, forming a massive roadblock to extensive market adoption.

Market Trends

The transition toward allogeneic, off-the-shelf mesenchymal stem cell therapies marks a crucial industry trend, resolving major drawbacks of autologous treatments like high costs, complicated production, and restricted scalability. By utilizing universal donor sources such as induced pluripotent stem cells, these allogeneic options pave the way for uniform, instantly accessible therapies that streamline supply chains and broaden patient reach. This method minimizes the differences between donors, thereby improving the reliability and effectiveness of the final product. Illustrating the expanding scope and mature clinical progress of these ready-to-use solutions, Cynata Therapeutics noted in its March 2025 Quarterly Activity Report that recruitment for a Phase 3 trial of its iPSC-derived MSC therapy for osteoarthritis, CYP-004, was successfully finalized with 321 enrollees.

At the same time, the emergence of cell-free treatments and MSC-derived exosomes constitutes a major breakthrough, shifting the focus from transplanting whole cells to indirectly utilizing the healing properties of MSCs. Functioning as nanoscale carriers, exosomes transport biomolecules essential for cellular communication and present notable benefits over live cells, including better safety profiles, lower immune reactions, and simplified storage and administration. This evolution enables fresh treatment strategies for multiple ailments by employing the paracrine functions of MSCs without the complications inherent in administering live cells. Reflecting the rising commercial appeal of this sector, Medical Buyer reported that the American firm Mdxhealth purchased Exosome Diagnostics from Bio-Techne in September 2025 for $15 million, emphasizing the strong financial backing and market worth of exosome innovations.

Key Market Players

  • Thermo Fisher Scientific, Inc
  • Cell Applications, Inc
  • Axol Biosciences Ltd
  • Cytori Therapeutics Inc
  • StemCell Technologies Canada Inc.
  • Cyagen Biomodels LLC
  • Celprogen Inc
  • BrainStorm Cell Limited
  • Stemedica Cell Technologies Inc
  • Merck KGaA

Report Scope

In this report, the Global Mesenchymal Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mesenchymal Stem Cells Market, By Product & Services

  • Products
  • Services

Mesenchymal Stem Cells Market, By Workflow

  • Cell Sourcing & Isolation
  • Culture & Cryopreservation
  • Differentiation
  • Characterization

Mesenchymal Stem Cells Market, By Type

  • Autologous
  • Allogeneic

Mesenchymal Stem Cells Market, By Source of Isolation

  • Bone Marrow
  • Cord Blood
  • Peripheral Blood
  • Fallopian Tube
  • Fetal Liver
  • Lung
  • Adipose Tissues

Mesenchymal Stem Cells Market, By Indication

  • Bone And Cartilage Repair
  • Cardiovascular Disease
  • Inflammatory And Immunological Diseases
  • Liver Diseases
  • Cancer
  • GvHD
  • Others

Mesenchymal Stem Cells Market, By Application

  • Disease Modelling
  • Drug Development & Discovery
  • Stem Cell Banking
  • Tissue Engineering
  • Toxicology Studies
  • Others

Mesenchymal Stem Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mesenchymal Stem Cells Market.

Available Customizations:

Global Mesenchymal Stem Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mesenchymal Stem Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Services (Products(Cells & Cell Lines, Kits, Media, & Reagents, Others), Services)
    • 5.2.2. By Workflow (Cell Sourcing & Isolation, Culture & Cryopreservation, Differentiation, Characterization)
    • 5.2.3. By Type (Autologous, Allogeneic)
    • 5.2.4. By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues)
    • 5.2.5. By Indication (Bone And Cartilage Repair, Cardiovascular Disease, Inflammatory And Immunological Diseases, Liver Diseases, Cancer, GvHD, Others)
    • 5.2.6. By Application (Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Mesenchymal Stem Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Services
    • 6.2.2. By Workflow
    • 6.2.3. By Type
    • 6.2.4. By Source of Isolation
    • 6.2.5. By Indication
    • 6.2.6. By Application
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Mesenchymal Stem Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Services
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Type
        • 6.3.1.2.4. By Source of Isolation
        • 6.3.1.2.5. By Indication
        • 6.3.1.2.6. By Application
    • 6.3.2. Canada Mesenchymal Stem Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Services
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Type
        • 6.3.2.2.4. By Source of Isolation
        • 6.3.2.2.5. By Indication
        • 6.3.2.2.6. By Application
    • 6.3.3. Mexico Mesenchymal Stem Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Services
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Type
        • 6.3.3.2.4. By Source of Isolation
        • 6.3.3.2.5. By Indication
        • 6.3.3.2.6. By Application

7. Europe Mesenchymal Stem Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Services
    • 7.2.2. By Workflow
    • 7.2.3. By Type
    • 7.2.4. By Source of Isolation
    • 7.2.5. By Indication
    • 7.2.6. By Application
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Mesenchymal Stem Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Services
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Type
        • 7.3.1.2.4. By Source of Isolation
        • 7.3.1.2.5. By Indication
        • 7.3.1.2.6. By Application
    • 7.3.2. France Mesenchymal Stem Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Services
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Type
        • 7.3.2.2.4. By Source of Isolation
        • 7.3.2.2.5. By Indication
        • 7.3.2.2.6. By Application
    • 7.3.3. United Kingdom Mesenchymal Stem Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Services
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Type
        • 7.3.3.2.4. By Source of Isolation
        • 7.3.3.2.5. By Indication
        • 7.3.3.2.6. By Application
    • 7.3.4. Italy Mesenchymal Stem Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Services
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Type
        • 7.3.4.2.4. By Source of Isolation
        • 7.3.4.2.5. By Indication
        • 7.3.4.2.6. By Application
    • 7.3.5. Spain Mesenchymal Stem Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Services
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Type
        • 7.3.5.2.4. By Source of Isolation
        • 7.3.5.2.5. By Indication
        • 7.3.5.2.6. By Application

8. Asia Pacific Mesenchymal Stem Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Services
    • 8.2.2. By Workflow
    • 8.2.3. By Type
    • 8.2.4. By Source of Isolation
    • 8.2.5. By Indication
    • 8.2.6. By Application
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Mesenchymal Stem Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Services
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Type
        • 8.3.1.2.4. By Source of Isolation
        • 8.3.1.2.5. By Indication
        • 8.3.1.2.6. By Application
    • 8.3.2. India Mesenchymal Stem Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Services
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Type
        • 8.3.2.2.4. By Source of Isolation
        • 8.3.2.2.5. By Indication
        • 8.3.2.2.6. By Application
    • 8.3.3. Japan Mesenchymal Stem Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Services
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Type
        • 8.3.3.2.4. By Source of Isolation
        • 8.3.3.2.5. By Indication
        • 8.3.3.2.6. By Application
    • 8.3.4. South Korea Mesenchymal Stem Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Services
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Type
        • 8.3.4.2.4. By Source of Isolation
        • 8.3.4.2.5. By Indication
        • 8.3.4.2.6. By Application
    • 8.3.5. Australia Mesenchymal Stem Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Services
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Type
        • 8.3.5.2.4. By Source of Isolation
        • 8.3.5.2.5. By Indication
        • 8.3.5.2.6. By Application

9. Middle East & Africa Mesenchymal Stem Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Services
    • 9.2.2. By Workflow
    • 9.2.3. By Type
    • 9.2.4. By Source of Isolation
    • 9.2.5. By Indication
    • 9.2.6. By Application
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Mesenchymal Stem Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Services
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Type
        • 9.3.1.2.4. By Source of Isolation
        • 9.3.1.2.5. By Indication
        • 9.3.1.2.6. By Application
    • 9.3.2. UAE Mesenchymal Stem Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Services
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Type
        • 9.3.2.2.4. By Source of Isolation
        • 9.3.2.2.5. By Indication
        • 9.3.2.2.6. By Application
    • 9.3.3. South Africa Mesenchymal Stem Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Services
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Type
        • 9.3.3.2.4. By Source of Isolation
        • 9.3.3.2.5. By Indication
        • 9.3.3.2.6. By Application

10. South America Mesenchymal Stem Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Services
    • 10.2.2. By Workflow
    • 10.2.3. By Type
    • 10.2.4. By Source of Isolation
    • 10.2.5. By Indication
    • 10.2.6. By Application
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Mesenchymal Stem Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Services
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Type
        • 10.3.1.2.4. By Source of Isolation
        • 10.3.1.2.5. By Indication
        • 10.3.1.2.6. By Application
    • 10.3.2. Colombia Mesenchymal Stem Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Services
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Type
        • 10.3.2.2.4. By Source of Isolation
        • 10.3.2.2.5. By Indication
        • 10.3.2.2.6. By Application
    • 10.3.3. Argentina Mesenchymal Stem Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Services
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Type
        • 10.3.3.2.4. By Source of Isolation
        • 10.3.3.2.5. By Indication
        • 10.3.3.2.6. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Mesenchymal Stem Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cell Applications, Inc
  • 15.3. Axol Biosciences Ltd
  • 15.4. Cytori Therapeutics Inc
  • 15.5. StemCell Technologies Canada Inc.
  • 15.6. Cyagen Biomodels LLC
  • 15.7. Celprogen Inc
  • 15.8. BrainStorm Cell Limited
  • 15.9. Stemedica Cell Technologies Inc
  • 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer